Return on Equity (ROE)
since 2005
Calculation
Regeneron Pharmaceuticals Inc., ROE, long-term trends, calculation
| ROE | = | 100 | × | Net income (loss)1 | ÷ | Stockholders’ equity1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2020 | 31.86% | = | 100 | × | 3,513,200 | ÷ | 11,025,300 |
| Dec 31, 2019 | 19.08% | = | 100 | × | 2,115,800 | ÷ | 11,089,700 |
| Dec 31, 2018 | 27.91% | = | 100 | × | 2,444,400 | ÷ | 8,757,300 |
| Dec 31, 2017 | 19.51% | = | 100 | × | 1,198,511 | ÷ | 6,144,078 |
| Dec 31, 2016 | 20.13% | = | 100 | × | 895,522 | ÷ | 4,449,245 |
| Dec 31, 2015 | 17.40% | = | 100 | × | 636,056 | ÷ | 3,654,837 |
| Dec 31, 2014 | 13.69% | = | 100 | × | 348,074 | ÷ | 2,542,325 |
| Dec 31, 2013 | 21.74% | = | 100 | × | 424,362 | ÷ | 1,952,076 |
| Dec 31, 2012 | 60.24% | = | 100 | × | 750,269 | ÷ | 1,245,385 |
| Dec 31, 2011 | -45.65% | = | 100 | × | (221,760) | ÷ | 485,732 |
| Dec 31, 2010 | -19.79% | = | 100 | × | (104,468) | ÷ | 527,815 |
| Dec 31, 2009 | -17.10% | = | 100 | × | (67,830) | ÷ | 396,762 |
| Dec 31, 2008 | -19.75% | = | 100 | × | (82,710) | ÷ | 418,852 |
| Dec 31, 2007 | -22.94% | = | 100 | × | (105,600) | ÷ | 460,267 |
| Dec 31, 2006 | -47.24% | = | 100 | × | (102,337) | ÷ | 216,624 |
| Dec 31, 2005 | -83.72% | = | 100 | × | (95,446) | ÷ | 114,002 |
Based on: 10-K (filing date: 2021-02-08), 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-12), 10-K (filing date: 2014-02-13), 10-K (filing date: 2013-02-15), 10-K (filing date: 2012-02-21), 10-K (filing date: 2011-02-17), 10-K (filing date: 2010-02-18), 10-K (filing date: 2009-02-26), 10-K (filing date: 2008-02-27), 10-K (filing date: 2007-03-12), 10-K (filing date: 2006-02-28).
1 US$ in thousands
Comparison to Competitors
Regeneron Pharmaceuticals Inc., ROE, long-term trends, comparison to competitors
| Regeneron Pharmaceuticals Inc. | Abbott Laboratories | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Eli Lilly & Co. | Gilead Sciences Inc. | Illumina Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Vertex Pharmaceuticals Inc. | Zoetis Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2020 | 31.86% | 13.71% | 35.30% | 77.20% | -23.84% | 109.79% | — | 13.98% | 23.25% | — | — | 31.22% | 43.46% |
| Dec 31, 2019 | 19.08% | 11.86% | — | 81.07% | 6.66% | 319.09% | 23.91% | 21.72% | 25.42% | 37.99% | 25.77% | 19.34% | 55.39% |
| Dec 31, 2018 | 27.91% | 7.76% | — | 67.15% | 35.07% | 32.88% | 25.51% | 21.98% | 25.60% | 23.30% | 17.59% | 47.28% | 65.35% |
| Dec 31, 2017 | 19.51% | 1.54% | 104.16% | 7.84% | 8.58% | -1.76% | 22.64% | 26.41% | 2.16% | 6.97% | 29.47% | 12.99% | 48.81% |
| Dec 31, 2016 | 20.13% | 6.82% | 128.41% | 25.85% | 27.55% | 19.54% | 71.48% | 21.06% | 23.49% | 9.78% | 12.12% | -9.69% | 55.21% |
| Dec 31, 2015 | 17.40% | 20.85% | 130.39% | 24.71% | 10.97% | 16.53% | 97.70% | 24.97% | 21.66% | 9.94% | 10.75% | -59.19% | 31.74% |
| Dec 31, 2014 | 13.69% | 10.61% | 101.84% | 20.01% | 13.49% | 15.55% | 78.45% | 24.16% | 23.40% | 24.50% | 12.81% | -68.70% | 44.47% |
| Dec 31, 2013 | 21.74% | 10.23% | 91.90% | 23.00% | 16.91% | 26.57% | 27.05% | 8.17% | 18.68% | 8.85% | 28.83% | -32.81% | 53.62% |
| Dec 31, 2012 | 60.24% | 22.32% | 156.85% | 22.80% | 14.39% | 27.69% | 27.84% | 11.47% | 16.74% | 11.63% | 17.93% | -10.71% | 10.83% |
| Dec 31, 2011 | -45.65% | 19.35% | — | 19.35% | 23.25% | 32.11% | 41.60% | 8.06% | 16.94% | 11.50% | 12.18% | 3.76% | — |
| Dec 31, 2010 | -19.79% | 20.66% | — | 19.32% | 19.74% | 40.82% | 49.48% | 10.43% | 23.57% | 1.58% | 9.40% | -149.74% | — |
| Dec 31, 2009 | -17.10% | 25.14% | — | 20.32% | 71.49% | 45.45% | 41.40% | 8.36% | 24.25% | 21.85% | 9.59% | -58.57% | — |
| Dec 31, 2008 | -19.75% | 27.92% | — | 20.58% | 42.86% | -30.76% | 48.43% | 5.95% | 30.46% | 41.63% | 14.08% | -192.51% | — |
| Dec 31, 2007 | -22.94% | 20.28% | — | 17.72% | 20.50% | 21.61% | 46.69% | -67.62% | 24.41% | 18.01% | 12.53% | -144.23% | — |
| Dec 31, 2006 | -47.24% | 12.22% | — | 15.56% | 15.86% | 24.25% | -65.54% | 16.16% | 28.11% | 25.25% | 27.10% | -40.89% | — |
| Dec 31, 2005 | -83.72% | 23.39% | — | 17.96% | 26.77% | 18.34% | 26.88% | -28.79% | 27.49% | 25.85% | 12.32% | -85.05% | — |
Based on: 10-K (filing date: 2021-02-08), 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-12), 10-K (filing date: 2014-02-13), 10-K (filing date: 2013-02-15), 10-K (filing date: 2012-02-21), 10-K (filing date: 2011-02-17), 10-K (filing date: 2010-02-18), 10-K (filing date: 2009-02-26), 10-K (filing date: 2008-02-27), 10-K (filing date: 2007-03-12), 10-K (filing date: 2006-02-28).
Comparison to Sector (Pharmaceuticals & Biotechnology)
Regeneron Pharmaceuticals Inc., ROE, long-term trends, comparison to sector (pharmaceuticals & biotechnology)
| Regeneron Pharmaceuticals Inc. | Pharmaceuticals & Biotechnology | |
|---|---|---|
| Dec 31, 2020 | 31.86% | — |
| Dec 31, 2019 | 19.08% | 29.60% |
| Dec 31, 2018 | 27.91% | 27.94% |
| Dec 31, 2017 | 19.51% | 14.50% |
| Dec 31, 2016 | 20.13% | 23.11% |
| Dec 31, 2015 | 17.40% | 22.96% |
| Dec 31, 2014 | 13.69% | 21.88% |
| Dec 31, 2013 | 21.74% | 20.86% |
| Dec 31, 2012 | 60.24% | 19.43% |
| Dec 31, 2011 | -45.65% | 16.36% |
| Dec 31, 2010 | -19.79% | 14.94% |
| Dec 31, 2009 | -17.10% | 21.95% |
| Dec 31, 2008 | -19.75% | 23.51% |
| Dec 31, 2007 | -22.94% | 18.18% |
| Dec 31, 2006 | -47.24% | 22.85% |
| Dec 31, 2005 | -83.72% | 19.61% |
Based on: 10-K (filing date: 2021-02-08), 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-12), 10-K (filing date: 2014-02-13), 10-K (filing date: 2013-02-15), 10-K (filing date: 2012-02-21), 10-K (filing date: 2011-02-17), 10-K (filing date: 2010-02-18), 10-K (filing date: 2009-02-26), 10-K (filing date: 2008-02-27), 10-K (filing date: 2007-03-12), 10-K (filing date: 2006-02-28).
Comparison to Industry (Health Care)
Regeneron Pharmaceuticals Inc., ROE, long-term trends, comparison to industry (health care)
| Regeneron Pharmaceuticals Inc. | Health Care | |
|---|---|---|
| Dec 31, 2020 | 31.86% | — |
| Dec 31, 2019 | 19.08% | 23.37% |
| Dec 31, 2018 | 27.91% | 21.29% |
| Dec 31, 2017 | 19.51% | 13.56% |
| Dec 31, 2016 | 20.13% | 18.84% |
| Dec 31, 2015 | 17.40% | 18.48% |
| Dec 31, 2014 | 13.69% | 19.31% |
| Dec 31, 2013 | 21.74% | 18.98% |
| Dec 31, 2012 | 60.24% | 17.23% |
| Dec 31, 2011 | -45.65% | 15.96% |
| Dec 31, 2010 | -19.79% | 14.48% |
| Dec 31, 2009 | -17.10% | 19.23% |
| Dec 31, 2008 | -19.75% | 19.21% |
| Dec 31, 2007 | -22.94% | 16.90% |
| Dec 31, 2006 | -47.24% | 18.60% |
| Dec 31, 2005 | -83.72% | 19.18% |
Based on: 10-K (filing date: 2021-02-08), 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-12), 10-K (filing date: 2014-02-13), 10-K (filing date: 2013-02-15), 10-K (filing date: 2012-02-21), 10-K (filing date: 2011-02-17), 10-K (filing date: 2010-02-18), 10-K (filing date: 2009-02-26), 10-K (filing date: 2008-02-27), 10-K (filing date: 2007-03-12), 10-K (filing date: 2006-02-28).